KRAS and non-small cell lung carcinoma: Currently, sotorasib is approved in the EU at 960 mg daily for KRAS G12C advanced mutated non-small cell lung cancer, but the access has been withdrawn in France following the phase 3 (CodeBreak 200) results [79].